Global Hematological Malignancies Drugs Market

Report ID : 1211 | Published : 2022-03-25 | Pages: | Format:

The global Hematological Malignancies Drugs market size was accounted at USD 13.76 Bn in 2021; It is projected to grow at a compound annual growth rate (CAGR) of 13.7% from 2022 to 2030. Hematologic malignancies are cancers that most often start in the bone marrow or the immune system cells. Lymphom, leukemia, and multiple myeloma are the three most common blood malignancies. The development of innovative agents has contributed to improved outcomes for cancer patients in recent years, resulting in significant advancement in the field of cancer therapy. The COVID19 pandemic, on the other hand, has hampered current cancer patient treatments. Because of their immunosuppression, patients with haematological malignancies appear to be extremely prone to Covid-19 infection.

The multiple factors driving the growth of the Hematological Malignancies Drugs Market  include the rising hematological malignancy cases, technological advances in therapy techniques, favourable regulatory environment, growing government funding for the R&D of innovative cancer therapies, spreading public awareness regarding the benefits of advanced blood cancer therapeutics, and the high demand for cost-efficient malignancy treatments. The increasing incidences of leukemia, lymphoma, and multiple myeloma cases led to the emergence of advanced therapeutics. For instance, in October 2021, Novartis acquired the US FDA approval for Scemblix (asciminib) to treat chronic myeloid leukemia (CML). Also, Bristol Myers Squibb (US) received U.S. FDA approval for Istodax (romidepsin), a histone deacetylase (HDAC) inhibitor, as monotherapy for the treatment of peripheral T-cell lymphoma (PTCL) in adult patients who have received at least one prior therapy. Thus, R&D activities are expected to offer new growth opportunities for the Hematological Malignancies Drugs Market  in the forthcoming years. 

However, the high cost of therapies, complex manufacturing methods, and the side effects of emerging therapies may inhibit market augmentation over the forecast years.

TheHematological Malignancies Drugs Market  is classified based on drugs, pipeline products, indications, and region. By drugs, the market is segmented into monoclonal antibodies (Blincyto (Blinatumomab), Besponsa (Inotuzumab Ozogamicin), Lumoxiti (Moxetumomab Pasudotox), Mylotarg (Gemtuzumab Ozogamicin), Opdivo (Nivolumab), AiRuiKa (Camrelizumab), Tyvyt (Sintilimab), Tislelizumab, Gazyva (Obinutuzumab), Zynlonta (Loncastuximab Tesirine-lpyl), Darzalex (Daratumumab), Blenrep (Belantamab Mafodotin-blmf), Keytruda (Pembrolizumab), Adcetris (Brentuximab Vedotin), Arzerra (Ofatumumab)) and CAR-T cell therapy (Tecartus (Brexucabtagene Autoleucel), Kymriah (Tisagenlecleucel), Yescarta (Axicabtagene Ciloleucel), Breyanzi (Lisocabtagene Maraleucel), Abecma (Idecabtagene Vicleucel)). By pipeline products, the market is grouped into monoclonal antibodies (Teclistamab, Iomab-B, Ublituximab, CS1001) and CAR-T cell therapy (Ciltacabtagene Autoleucel (JNJ-68284528)). The indications segment comprises leukemia (acute lymphoblastic leukemia, chronic lymphoblastic leukemia, acute myeloid leukemia), lymphoma (Hodgkin’s lymphoma and Non-Hodgkin’s lymphoma), and multiple myeloma. Region-wise, the market is studied across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

North America dominated theHematological Malignancies Drugs Market  in 2021 and is expected to continue its trend over the forecast period (2022-2030) due to the surging R&D funding for malignancy therapeutics and the growing incidences of leukemia and lymphoma in this region.

Few key players operating in theHematological Malignancies Drugs Market  are  AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline plc, Immune-Onc Therapeutics, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, and others.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Hematological Malignancies Drugs Market Snapshot

Chapter 4. Global Hematological Malignancies Drugs Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Clinical Trial/Pipeline Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Route of Administration, Estimates & Trend Analysis

5.1. By Drugs, & Market Share, 2020 & 2030

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Drugs:

5.2.1. Monoclonal Antibodies

5.2.1.1. Blincyto (Blinatumomab)

5.2.1.2.  Besponsa (Inotuzumab Ozogamicin)

5.2.1.3.  Lumoxiti (Moxetumomab Pasudotox)

5.2.1.4.  Mylotarg (Gemtuzumab Ozogamicin)

5.2.1.5.  Opdivo (Nivolumab)

5.2.1.6.  AiRuiKa (Camrelizumab)

5.2.1.7.  Tyvyt (Sintilimab)

5.2.1.8.  Tislelizumab

5.2.1.9.  Gazyva (Obinutuzumab)

5.2.1.10.  Zynlonta (Loncastuximab Tesirine-lpyl)

5.2.1.11.  Darzalex (Daratumumab)

5.2.1.12.  Blenrep (Belantamab Mafodotin-blmf)

5.2.1.13.  Keytruda (Pembrolizumab)

5.2.1.14.  Adcetris (Brentuximab Vedotin)

5.2.1.15.  Arzerra (Ofatumumab)

5.2.2. CAR-T Cell Therapy

5.2.2.1. Tecartus (Brexucabtagene Autoleucel)

5.2.2.2.  Kymriah (Tisagenlecleucel)

5.2.2.3.  Yescarta (Axicabtagene Ciloleucel)

5.2.2.4.  Breyanzi (Lisocabtagene Maraleucel)

5.2.2.5.  Abecma (Idecabtagene Vicleucel)

Chapter 6. Market Segmentation 2: By Indications Estimates & Trend Analysis

6.1. By Pipeline Products & Market Share, 2020 & 2030

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Pipeline Products:

6.2.1. Monoclonal Antibodies

6.2.1.1. Teclistamab

6.2.1.2.  Iomab-B

6.2.1.3.  Ublituximab

6.2.1.4.  CS1001

6.2.2. CAR-T Cell Therapy

6.2.2.1. Ciltacabtagene Autoleucel (JNJ-68284528)

Chapter 7. Market Segmentation 3: By Pipeline Products Estimates & Trend Analysis

7.1. By Indications & Market Share, 2020& 2030

7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Indications:

7.2.1. Leukemia

7.2.1.1. Acute Lymphoblastic Leukemia

7.2.1.2.  Chronic Lymphoblastic Leukemia

7.2.1.3.  Acute Myeloid Leukemia

7.2.2. Lymphoma

7.2.2.1. Hodgkin’s Lymphoma

7.2.2.2.  Non-Hodgkin’s Lymphoma

7.2.3. Multiple Myeloma

Chapter 8. Hematological Malignancies Drugs Market Segmentation 5: Regional Estimates & Trend Analysis

8.1. North America

8.1.1. North America Hematological Malignancies Drugs Market revenue (US$ Million) estimates and forecasts By Drugs, 2019-2030

8.1.2. North America Hematological Malignancies Drugs Market revenue (US$ Million) estimates and forecasts By Pipeline Products, 2019-2030

8.1.3. North America Hematological Malignancies Drugs Market revenue (US$ Million) estimates and forecasts By Indications, 2019-2030

8.1.4. North America Hematological Malignancies Drugs Market revenue (US$ Million) estimates and forecasts by country, 2019-2030

8.2. Europe

8.2.1. Europe Hematological Malignancies Drugs Market revenue (US$ Million) By Drugs, 2019-2030

8.2.2. Europe Hematological Malignancies Drugs Market revenue (US$ Million) By Pipeline Products, 2019-2030

8.2.3. Europe Hematological Malignancies Drugs Market revenue (US$ Million) By Indications, 2019-2030

8.2.4. Europe Hematological Malignancies Drugs Market revenue (US$ Million) by country, 2019-2030

8.3. Asia Pacific

8.3.1. Asia Pacific Hematological Malignancies Drugs Market revenue (US$ Million) By Drugs, 2019-2030

8.3.2. Asia Pacific Hematological Malignancies Drugs Market revenue (US$ Million) By Pipeline Products, 2019-2030

8.3.3. Asia Pacific Hematological Malignancies Drugs Market revenue (US$ Million) By Indications, 2019-2030

8.3.4. Asia Pacific Hematological Malignancies Drugs Market revenue (US$ Million) by country, 2019-2030

8.4. Latin America

8.4.1. Latin America Hematological Malignancies Drugs Market revenue (US$ Million) By Drugs, (US$ Million) 2019-2030

8.4.2. Latin America Hematological Malignancies Drugs Market revenue (US$ Million) By Pipeline Products, (US$ Million) 2019-2030

8.4.3. Latin America Hematological Malignancies Drugs Market revenue (US$ Million) By Indications, (US$ Million) 2019-2030

8.4.4. Latin America Hematological Malignancies Drugs Market revenue (US$ Million) by country, 2019-2030

8.5. Middle East & Africa

8.5.1. Middle East & Africa Hematological Malignancies Drugs Market revenue (US$ Million) By Drugs, (US$ Million) 2019-2030

8.5.2. Middle East & Africa Hematological Malignancies Drugs Market revenue (US$ Million) By Pipeline Products, (US$ Million) 2019-2030

8.5.3. Middle East & Africa Hematological Malignancies Drugs Market revenue (US$ Million) By Indications, (US$ Million) 2019-2030

8.5.4. Middle East & Africa Hematological Malignancies Drugs Market revenue (US$ Million) by country, 2019-2030

Chapter 9. Competitive Landscape

9.1. Major Mergers and Acquisitions/Strategic Alliances

9.2. Company Profiles

9.2.1. AbbVie Inc.

9.2.2. Amgen Inc.

9.2.3. Bristol-Myers Squibb Company

9.2.4. F. Hoffmann-La Roche Ltd.

9.2.5. Gilead Sciences, Inc.

9.2.6. GlaxoSmithKline plc

9.2.7. Immune-Onc Therapeutics, Inc.

9.2.8. Johnson & Johnson Services, Inc.

9.2.9. Merck & Co., Inc.

9.2.10. Novartis International AG

9.2.11. Pfizer Inc.

9.2.12. Sanofi S.A.

9.2.13. Takeda Pharmaceutical Company Limited

9.2.14. Other Prominent Players

Global Hematological Malignancies Drugs Market , by Drugs, 2022-2030 (Valu US$ Mn)

  • Monoclonal Antibodies
  • Blincyto (Blinatumomab)
  • Besponsa (Inotuzumab Ozogamicin)
  • Lumoxiti (Moxetumomab Pasudotox)
  • Mylotarg (Gemtuzumab Ozogamicin)
  • Opdivo (Nivolumab)
  • AiRuiKa (Camrelizumab)
  • Tyvyt (Sintilimab)
  • Tislelizumab
  • Gazyva (Obinutuzumab)
  • Zynlonta (Loncastuximab Tesirine-lpyl)
  • Darzalex (Daratumumab)
  • Blenrep (Belantamab Mafodotin-blmf)
  • Keytruda (Pembrolizumab)
  • Adcetris (Brentuximab Vedotin)
  • Arzerra (Ofatumumab
  • CAR-T Cell Therapy
  • Tecartus (Brexucabtagene Autoleucel)
  • Kymriah (Tisagenlecleucel)
  • Yescarta (Axicabtagene Ciloleucel)
  • Breyanzi (Lisocabtagene Maraleucel)
  • Abecma (Idecabtagene Vicleucel)

Global Hematological Malignancies Drugs Market , by Pipeline Products, 2022-2030 (Valu US$ Mn)

  • Monoclonal Antibodies
  • Teclistamab
  • Iomab-B
  • Ublituximab
  • CS1001
  • CAR-T Cell Therapy
  • Ciltacabtagene Autoleucel (JNJ-68284528)

Global Hematological Malignancies Drugs Market , by Indications, 2022-2030 (Value US$ Mn)

  • Leukemia
  • Acute Lymphoblastic Leukemia
  • Chronic Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Lymphoma
  • Hodgkin’s Lymphoma
  • Non-Hodgkin’s Lymphoma
  • Multiple Myeloma

Global Hematological Malignancies Drugs Market , by Region, 2022-2030 (Value US$ Mn)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

North AmericaHematological Malignancies Drugs Market , by Country, 2022-2030 (Value US$ Mn)

  • U.S.
  • Canada

Europe Hematological Malignancies Drugs Market , by Country, 2022-2030 (Value US$ Mn)

  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia PacificHematological Malignancies Drugs Market , by Country, 2022-2030 (Value US$ Mn)

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America Hematological Malignancies Drugs Market , by Country, 2022-2030 (Value US$ Mn)

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa Hematological Malignancies Drugs Market , by Country, 2022-2030 (Value US$ Mn)

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Landscape

  • AbbVie Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Immune-Onc Therapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited

Other Prominent Players

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?

Frequently Asked Questions

Who are the Key Players in the Hematological Malignancies Drugs Market?

Hematological Malignancies Drugs Market worth $ 42.78 Billion by 2030

CAGR of 13.7 % during the forecast period of 2022-2030.

Our Clients